Drugs for Hypertension
March 13, 2017 (Issue: 1516)
in the US and their dosages, adverse effects, and
costs are listed in the tables.
Treatment of hypertensive urgencies and emergencies
is not discussed here.
- PK Whelton et al. 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71:2199.
- American College of Cardiology. ASCVD risk estimator plus. Available at: http://tools.acc.org. Accessed January 31, 2018.
- A Qaseem et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2017; 166:430.
- AAFP. AAFP decides to not endorse AHA/ACC hypertension guidelines. Available at: https://www.aafp.org. Accessed January 26, 2018.
- Has been removed.
- JT Wright Jr et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832.
- GC Roush et al. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19:5.
- VM Musini et al. Blood pressure-lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2015; 5:CD003825.
- DA Calhoun et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014; 63:451.
- DA Calhoun and WB White. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2:462.
- Drugs for chronic heart failure. Med Lett Drugs Ther 2015; 57:9.
- Aliskiren (Tekturna) for hypertension. Med Lett Drugs Ther 2007; 49:29.
- F Turnbull et al. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527.
- K Jamerson et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.
- WH Frishman and E Saunders. ß-adrenergic blockers. J Clin Hypertens (Greenwich) 2011; 13:649.
- CS Wiysonge et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012; 11:CD002003.
- GL Bakris et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.
- Nebivolol (Bystolic) for hypertension. Med Lett Drugs Ther 2008; 50:17.
- J Fongemie and E Felix-Getzik. A review of nebivolol pharmacology and clinical evidence. Drugs 2015; 75:1349.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283:1967.
- P Smith et al. Nifedipine in pregnancy. BJOG 2000; 107:299.
- WF Peacock IV et al. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med 2012; 30:981.
- SN Molvi et al. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet 2012; 285:1553.
- MY Yacoob et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension 2013; 62:375.
- C Lydakis et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12:541.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
